Abstracts tagged "osteo-anabolics and osteoporosis"

Abstract Number: 1890 • 2017 ACR/ARHP Annual Meeting
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Kenneth Saag¹, Paul D Miller², Felicia Cosman^3,4, Lorraine A Fitzpatrick⁵, Gary Hattersley⁶, Robert Gut⁶, Bruce Mitlak⁶, John P Bilezikian⁴ and Robin K Dore⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Colorado Center for Bone Research, Lakewood, CO, ³Helen Hayes Hospital, West Haverstraw, NY, ⁴Columbia University College of Physicians and Surgeons, New York, NY, ⁵Chief Medical Officer, Radius Health, Inc., Waltham, MA, ⁶Radius Health, Inc., Waltham, MA, ⁷Robin K Dore, MD, Inc., Tustin, CA
Background/Purpose: In the ACTIVE phase III trial, postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide…
Abstract Number: 338 • 2016 ACR/ARHP Annual Meeting
Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline
F Cosman¹, Gary Hattersley², PD Miller³, Ming-Yu Hu⁴, Luis Augusto Tavares Russo⁵, Bente Riis⁶, Greg Williams⁷ and Lorraine Fitzpatrick⁸, ¹Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY, ²Research, Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴Biometrics, Radius Health, Inc., Waltham, MA, ⁵CCBR Brasil, Rua Mena Barreto, 33 Botofogo, 22271, Rio de Janeiro, Brazil, ⁶Nordic Biosciences A/S, 2730 Herlev, Denmark, ⁷Clinical Development, Radius Health, Inc., Waltham, MA, ⁸Chief Medical Officer, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide is a novel 34 amino acid peptide created to be a potent and selective activator of the PTH 1 receptor signaling pathway and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].